| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1015678887 |
| P356 | DOI | 10.1186/1471-2407-12-91 |
| P932 | PMC publication ID | 3342883 |
| P698 | PubMed publication ID | 22429801 |
| P5875 | ResearchGate publication ID | 221722479 |
| P50 | author | Jeremy A. Squire | Q39802515 |
| P2093 | author name string | Jian Chen | |
| Ken Evans | |||
| Harriet Feilotter | |||
| Paul C Park | |||
| Joseph Geraci | |||
| Moyez Dharsee | |||
| Jieran Li | |||
| Madhuri Koti | |||
| Paulo Nuin | |||
| Johanne Weberpals | |||
| Timothy Childs | |||
| Scott Davey | |||
| Alexandria M Haslehurst | |||
| P2860 | cites work | Ovarian carcinoma subtypes are different diseases: implications for biomarker studies | Q21563402 |
| Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression | Q24633875 | ||
| The basics of epithelial-mesenchymal transition | Q24652992 | ||
| Analyzing real-time PCR data by the comparative C(T) method | Q28131831 | ||
| The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it | Q28254798 | ||
| Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: a study of hepatocellular carcinoma. | Q51861254 | ||
| Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer | Q73366531 | ||
| Microarray analysis of gene expression during epithelial-mesenchymal transformation | Q80359005 | ||
| Diagnostic markers for early detection of ovarian cancer | Q80656320 | ||
| Chemotherapy: Current drugs still have potential in advanced ovarian cancer | Q83955877 | ||
| Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator Twist1 | Q28275597 | ||
| Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis | Q28283104 | ||
| Snail blocks the cell cycle and confers resistance to cell death | Q28572344 | ||
| Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. | Q33529528 | ||
| Drug transporters of platinum-based anticancer agents and their clinical significance | Q33798867 | ||
| Ovarian cancer: epidemiology, biology, and prognostic factors | Q33959805 | ||
| Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression | Q34655105 | ||
| Slug enhances invasion ability of pancreatic cancer cells through upregulation of matrix metalloproteinase-9 and actin cytoskeleton remodeling | Q35073648 | ||
| Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer | Q35230326 | ||
| Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. | Q35426250 | ||
| Biomarkers for epithelial-mesenchymal transitions | Q37209254 | ||
| Gene-expression profiling in epithelial ovarian cancer | Q37224303 | ||
| EMT: when epithelial cells decide to become mesenchymal-like cells | Q37504554 | ||
| Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. | Q37504561 | ||
| The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs | Q37524079 | ||
| Metastasis mechanisms | Q37580464 | ||
| The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer | Q37636689 | ||
| Pharmacogenomics of taxane/platinum therapy in ovarian cancer | Q37643317 | ||
| Epithelial-mesenchymal transition in cancer development and its clinical significance | Q37644546 | ||
| Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer | Q37655607 | ||
| Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes | Q37709923 | ||
| Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer | Q37728847 | ||
| Current clinical use of biomarkers for epithelial ovarian cancer | Q37770908 | ||
| Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget | Q37840946 | ||
| Cancer early dissemination: cancerous epithelial-mesenchymal transdifferentiation and transforming growth factor β signalling | Q37863348 | ||
| Molecular mechanisms of cisplatin resistance | Q37926477 | ||
| Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells | Q38519160 | ||
| Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780. | Q39523974 | ||
| Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern | Q39617314 | ||
| Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor | Q39637704 | ||
| Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells | Q39834964 | ||
| An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. | Q40172885 | ||
| Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells | Q40214416 | ||
| Genetics of kidney development. | Q41061764 | ||
| Structural studies of interactions between anticancer platinum drugs and DNA. | Q41434234 | ||
| Twist function is required for the morphogenesis of the cephalic neural tube and the differentiation of the cranial neural crest cells in the mouse embryo | Q48567446 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| cisplatin | Q412415 | ||
| P304 | page(s) | 91 | |
| P577 | publication date | 2012-03-19 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer | |
| P478 | volume | 12 |
| Q90736000 | A Novel Role for the Tumor Suppressor Gene ITF2 in Tumorigenesis and Chemotherapy Response |
| Q36545528 | A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype |
| Q90367226 | A novel miR-200c/c-myc negative regulatory feedback loop is essential to the EMT process, CSC biology and drug sensitivity in nasopharyngeal cancer |
| Q99564694 | ASB13 inhibits breast cancer metastasis through promoting SNAI2 degradation and relieving its transcriptional repression of YAP |
| Q35996869 | Aberrant expression of Notch1/numb/snail signaling, an epithelial mesenchymal transition related pathway, in adenomyosis |
| Q41612891 | Acquired platinum resistance involves epithelial to mesenchymal transition through ubiquitin ligase FBXO32 dysregulation |
| Q49235662 | Activation of the LKB1‑SIK1 signaling pathway inhibits the TGF‑β‑mediated epithelial‑mesenchymal transition and apoptosis resistance of ovarian carcinoma cells |
| Q37596157 | Acute lung injury and fibrosis in a baboon model of Escherichia coli sepsis. |
| Q53536514 | Akt2/ZEB2 may be a biomarker for exfoliant cells in ascitic fluid in advanced grades of serous ovarian carcinoma. |
| Q38872816 | Anti-Cancer Activity of Solanum nigrum (AESN) through Suppression of Mitochondrial Function and Epithelial-Mesenchymal Transition (EMT) in Breast Cancer Cells. |
| Q38295332 | Autophagy positively regulates DNA damage recognition by nucleotide excision repair |
| Q64926835 | CAPE-pNO2 Inhibited the Growth and Metastasis of Triple-Negative Breast Cancer via the EGFR/STAT3/Akt/E-Cadherin Signaling Pathway. |
| Q35067887 | CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling. |
| Q38703645 | CYT-Rx20 inhibits ovarian cancer cells in vitro and in vivo through oxidative stress-induced DNA damage and cell apoptosis |
| Q26864839 | Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention |
| Q47094357 | Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer. |
| Q90365564 | Circulating tumor cells and their advances to promote cancer metastasis and relapse, with focus on glioblastoma multiforme |
| Q39169544 | Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelial-mesenchymal transition-like changes |
| Q35176432 | Cisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/Snail axis in atypical teratoid/rhabdoid tumor cells |
| Q38799468 | Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer |
| Q38850621 | Concise Review: Stem Cells and Epithelial-Mesenchymal Transition in Cancer: Biological Implications and Therapeutic Targets. |
| Q92043014 | Contribution of Epithelial Plasticity to Therapy Resistance |
| Q91013857 | Controversies around epithelial-mesenchymal plasticity in cancer metastasis |
| Q38628964 | Current state of biomarkers in ovarian cancer prognosis |
| Q38906391 | DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma |
| Q33829740 | Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition |
| Q49936377 | Delphinidin induces apoptosis and inhibits epithelial-to-mesenchymal transition via the ERK/p38 MAPK-signaling pathway in human osteosarcoma cell lines |
| Q64375199 | Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling |
| Q36304712 | Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target |
| Q92825104 | Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells |
| Q33650801 | Downregulation of miR-218 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling |
| Q91668076 | Downregulation of nicotinamide N-methyltransferase inhibits migration and epithelial-mesenchymal transition of esophageal squamous cell carcinoma via Wnt/β-catenin pathway |
| Q34365738 | EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer |
| Q26781912 | EMT-Inducing Molecular Factors in Gynecological Cancers |
| Q38040369 | EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. |
| Q38704722 | Ectopic repression of receptor tyrosine kinase-like orphan receptor 2 inhibits malignant transformation of ovarian cancer cells by reversing epithelial-mesenchymal transition |
| Q45070718 | Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review |
| Q38044317 | Epithelial to mesenchymal transition as a portal to stem cell characters embedded in gene networks. |
| Q38992054 | Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. |
| Q49990003 | Epithelial-mesenchymal transition and plasticity in the developmental basis of cancer and fibrosis |
| Q91229377 | Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma |
| Q90010888 | Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer? |
| Q47138387 | Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: Mechanisms and clinical applications |
| Q37419295 | Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition. |
| Q33722983 | Ethaselen: a novel organoselenium anticancer agent targeting thioredoxin reductase 1 reverses cisplatin resistance in drug-resistant K562 cells by inducing apoptosis |
| Q36195495 | Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer |
| Q28468344 | Expression of epidermal growth factor‑like domain 7 may be a predictive marker of the effect of neoadjuvant chemotherapy for locally advanced uterine cervical cancer |
| Q42931053 | Expression of metastasis suppressor 1 in cervical carcinoma and the clinical significance |
| Q89967768 | Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy |
| Q35740047 | Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis |
| Q30446755 | Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules |
| Q38950425 | Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer |
| Q28542669 | Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells |
| Q39104716 | Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug. |
| Q55333460 | High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease. |
| Q52717949 | Human Cancer and Platelet Interaction, a Potential Therapeutic Target. |
| Q38756307 | Human papillomavirus oncoproteins differentially modulate epithelial-mesenchymal transition in 5-FU-resistant cervical cancer cells |
| Q88956858 | Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells |
| Q33686502 | Immunohistochemical analysis of NANOG expression and epithelial-mesenchymal transition in pulmonary sarcomatoid carcinoma |
| Q64976050 | Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin. |
| Q55078651 | Inhibition of DNA methyltransferase 1 by RNA interference reverses epithelial-mesenchymal transition in highly metastatic 95D lung cancer cells by inhibiting the Wnt signaling pathway. |
| Q92993185 | Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression |
| Q36167817 | Inhibition of Snail Family Transcriptional Repressor 2 (SNAI2) Enhances Multidrug Resistance of Hepatocellular Carcinoma Cells |
| Q37188588 | Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours |
| Q37706407 | Integrated genomic and molecular characterization of cervical cancer |
| Q28917139 | Integrin β4 promotes cell invasion and epithelial-mesenchymal transition through the modulation of Slug expression in hepatocellular carcinoma |
| Q33618652 | Involvement of AF1q/MLLT11 in the progression of ovarian cancer |
| Q45792633 | Knockdown of HMGN5 increases the chemosensitivity of human urothelial bladder cancer cells to cisplatin by targeting PI3K/Akt signaling |
| Q36419257 | Loss of Scribble Promotes Snail Translation through Translocation of HuR and Enhances Cancer Drug Resistance |
| Q90573040 | MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species |
| Q41018062 | MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells |
| Q58795253 | MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition |
| Q90136518 | MiR-486-5p inhibits IL-22-induced epithelial-mesenchymal transition of breast cancer cell by repressing Dock1 |
| Q40101851 | Microbial infection, inflammation and epithelial ovarian cancer |
| Q37096241 | Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer. |
| Q91761884 | Molecular Insights into miRNA-Driven Resistance to 5-Fluorouracil and Oxaliplatin Chemotherapy: miR-23b Modulates the Epithelial–Mesenchymal Transition of Colorectal Cancer Cells |
| Q48274587 | Molecular mechanisms of drug resistance in ovarian cancer. |
| Q36390287 | NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis |
| Q98288425 | Napabucasin overcomes cisplatin resistance in ovarian germ cell tumor-derived cell line by inhibiting cancer stemness |
| Q37745657 | New insights into therapeutic activity and anticancer properties of curcumin |
| Q29620083 | Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA |
| Q34447404 | OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets. |
| Q92435717 | Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway |
| Q47371762 | Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin |
| Q89746133 | Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract |
| Q50157919 | PD98059 impairs the cisplatin-resistance of ovarian cancer cells by suppressing ERK pathway and epithelial mesenchymal transition process |
| Q39085744 | Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression |
| Q60309932 | Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer |
| Q55404911 | Protein expression patterns in cancer-associated fibroblasts and cells undergoing the epithelial-mesenchymal transition in ovarian cancers. |
| Q91734145 | RNF43 ubiquitinates and degrades phosphorylated E-cadherin by c-Src to facilitate epithelial-mesenchymal transition in lung adenocarcinoma |
| Q28393939 | Radioactive (125)I seeds inhibit cell growth and epithelial-mesenchymal transition in human glioblastoma multiforme via a ROS-mediated signaling pathway |
| Q37684607 | Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer. |
| Q36124788 | Regulation of the protein stability of EMT transcription factors |
| Q28539044 | Resveratrol inhibits cisplatin-induced epithelial-to-mesenchymal transition in ovarian cancer cell lines |
| Q33880574 | Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells. |
| Q38244309 | Role of epithelial to mesenchymal transition proteins in gynecological cancers: pathological and therapeutic perspectives |
| Q37262987 | Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis. |
| Q38909048 | Roles and epigenetic regulation of epithelial-mesenchymal transition and its transcription factors in cancer initiation and progression |
| Q36303130 | SLUG is a direct transcriptional repressor of PTEN tumor suppressor |
| Q33639728 | SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour |
| Q37513779 | Sequence variation among members of the miR-200 microRNA family is correlated with variation in the ability to induce hallmarks of mesenchymal-epithelial transition in ovarian cancer cells. |
| Q89537605 | Silencing Snail Reverses Epithelial-Mesenchymal Transition and Increases Radiosensitivity in Hypopharyngeal Carcinoma |
| Q35168129 | Slug contributes to cancer progression by direct regulation of ERα signaling pathway |
| Q38872426 | Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133(+) pancreatic cancer cells |
| Q37295608 | Slug inhibits the proliferation and tumor formation of human cervical cancer cells by up-regulating the p21/p27 proteins and down-regulating the activity of the Wnt/β-catenin signaling pathway via the trans-suppression Akt1/p-Akt1 expression |
| Q34371410 | Slug is associated with poor survival in squamous cell carcinoma of the lung. |
| Q92512066 | Snail expression contributes to temozolomide resistance in glioblastoma |
| Q33597683 | TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells |
| Q96816912 | TGF-β induced EMT and stemness characteristics are associated with epigenetic regulation in lung cancer |
| Q26741846 | Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer |
| Q39454244 | Targeting Platelets for the Treatment of Cancer. |
| Q42317503 | Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer |
| Q89286757 | The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome |
| Q92856177 | The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance |
| Q42991719 | The Role of Platelet-Derived ADP and ATP in Promoting Pancreatic Cancer Cell Survival and Gemcitabine Resistance |
| Q38633203 | The epithelial-mesenchymal transition in cancer: a potential critical topic for translational proteomic research. |
| Q90749105 | The importance of epithelial-mesenchymal transition and autophagy in cancer drug resistance |
| Q27008375 | The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin |
| Q39061847 | The relationship between platinum drug resistance and epithelial-mesenchymal transition |
| Q38150596 | The role of EPH receptors in cancer-related epithelial-mesenchymal transition |
| Q37297523 | The role of nuclear β-catenin accumulation in the Twist2-induced ovarian cancer EMT. |
| Q35904547 | The role of photodynamic therapy in overcoming cancer drug resistance |
| Q38206587 | The therapeutic potential of targeting the epithelial-mesenchymal transition in cancer |
| Q47947313 | Thrombomodulin mediates the migration of cervical cancer cells through the regulation of epithelial-mesenchymal transition biomarkers |
| Q39114905 | Thrombomodulin mediates the progression of epithelial ovarian cancer cells |
| Q61453120 | UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells |
| Q64062880 | USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability |
| Q41098467 | Upregulation of CYP17A1 by Sp1-mediated DNA demethylation confers temozolomide resistance through DHEA-mediated protection in glioma |
| Q37337989 | Valproic acid inhibits irradiation-induced epithelial-mesenchymal transition and stem cell-like characteristics in esophageal squamous cell carcinoma |
| Q39000993 | Zinc finger E-box-binding homeobox 2 (ZEB2) regulated by miR-200b contributes to multi-drug resistance of small cell lung cancer |
| Q96132792 | lncRNA MALAT1 Promotes EMT Process and Cisplatin Resistance of Oral Squamous Cell Carcinoma via PI3K/AKT/m-TOR Signal Pathway |
| Q36830338 | miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN. |
Search more.